SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-20-121786
Filing Date
2020-11-05
Accepted
2020-11-05 16:06:30
Documents
61
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q tm2029621-3_10q.htm 10-Q 599463
2 EXHIBIT 31.1 tm2029621d3_ex31-1.htm EX-31.1 10594
3 EXHIBIT 31.2 tm2029621d3_ex31-2.htm EX-31.2 10694
4 EXHIBIT 32.1 tm2029621d3_ex32-1.htm EX-32.1 5035
  Complete submission text file 0001104659-20-121786.txt   5272902

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT cldx-20200930.xml EX-101.INS 1600118
6 XBRL TAXONOMY EXTENSION SCHEMA cldx-20200930.xsd EX-101.SCH 29150
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE cldx-20200930_cal.xml EX-101.CAL 45350
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE cldx-20200930_def.xml EX-101.DEF 110349
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE cldx-20200930_lab.xml EX-101.LAB 338765
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cldx-20200930_pre.xml EX-101.PRE 244029
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

IRS No.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-15006 | Film No.: 201290437
SIC: 2835 In Vitro & In Vivo Diagnostic Substances